Brazil’s DASA seals MD1 buy, as international expansion beckons
This article was originally published in Clinica
Diagn�sticos da América SA (DASA), the Brazilian lab diagnostics and imaging services giant, will be looking beyond its domestic market and towards international growth as part of a longer-term M&A strategy that has made it the dominant player in Brazil.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.